TherapeuticsMD, Inc.

As of March 31, 2026, TherapeuticsMD, Inc. carries a market capitalization of 20.37M, placing it among publicly traded companies globally. Its enterprise value stands at 18.13M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

TherapeuticsMD, Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

As of March 31, 2026, TherapeuticsMD, Inc. has 11.57M shares outstanding.

As of March 31, 2026, TherapeuticsMD, Inc. trades at a trailing price-to-earnings ratio of 131.55. The price-to-sales ratio is 7.02, and the price-to-book ratio stands at 0.87.

These figures are as of March 31, 2026. The EV/Sales ratio of 6.25 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. TherapeuticsMD, Inc. trades at an EV/FCF ratio of 7.76, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 18.13M versus a market cap of 20.37M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, TherapeuticsMD, Inc. maintains a current ratio of 3.11, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 21.62, indicating elevated leverage, while an interest coverage ratio of -528.00 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, TherapeuticsMD, Inc. posted a return on equity (ROE) of 0.67, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -8.40, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 0.47, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 0.55, useful for judging operating efficiency across full business cycles. The company generates approximately 2.90M in revenue per employee across its workforce of 1.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended March 31, 2026, TherapeuticsMD, Inc. recorded 27,683.20 in income tax expense. That works out to an effective tax rate of 27.12, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 102,081.80, leaving 154,852.90 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, TherapeuticsMD, Inc.'s stock has gained approximately 53.15% over the past 52 weeks. The 50-day moving average sits at 1.83, while the 200-day moving average is 1.83.

Over the twelve months ended March 31, 2026, TherapeuticsMD, Inc. generated 2.90M in revenue and converted that into 154,852.90 in net income, yielding earnings per share of 0.01. EBITDA reached -2.28M, while operating income came in at -3.24M.

As of March 31, 2026, TherapeuticsMD, Inc. holds 7.28M in cash and equivalents against 5.04M in total debt, resulting in a net debt position of -7.28M. Total book value stands at 23.33M, with working capital of 8.96M providing operational flexibility.

TherapeuticsMD, Inc. produced 2.33M in operating cash flow over the twelve months ended March 31, 2026.

These figures cover the twelve months ended March 31, 2026. The operating margin of -111.66 and net profit margin of 5.34 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 11.45, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt.

TherapeuticsMD, Inc.'s most recent stock split took place on May 9, 2022 with a 50:1 split ratio.

As of March 31, 2026, TherapeuticsMD, Inc. has an Altman Z-Score of -37.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.